Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/DMT/Neurocognitive Disorders

DMT for Neurocognitive Disorders

4 papers and 0 clinical trials exploring dmt as a treatment for neurocognitive disorders.

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
Indication55M+ people living with dementia worldwide

Neurocognitive Disorders

Neurocognitive disorders, including dementia, Alzheimer's disease, Parkinson's disease and traumatic brain injury, involve a progressive decline in memory, thinking and everyday function. Interest in psychedelics here rests on a strong biological rationale and early human safety signals, not on proven treatment: no completed controlled trial yet shows that psychedelics treat dementia or restore lost cognition.

Full Neurocognitive Disorders profile

Academic Research

4 papers
Open Accessindividual

DMT micro-phenomenology

Using micro-phenomenological interviews with 23 participants who received DMT during fMRI, the study shows DMT reliably produces deeply immersive presence experiences that unfold through a characteristic layering—initial multisensory effects followed by spatial, self-related and social reconfigurations. This structural and temporal mapping extends beyond concepts like ego dissolution to advance understanding of DMT's effects and the architecture of conscious experience, and demonstrates the value of systematic first‑person methods for comparing altered states.

Published
December 29, 2024
Journal
Preprints
Authors
Sanders, J. W., Milliere, R., Daily, Z. G., Carhart-Harris, R., Timmermann, C.
Open Accessindividual

N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain

This rat study (n=69) examined whether DMT (1mg/kg/h) administration achieves neuroprotection via Sig-1R activation during an experimentally induced forebrain ischemia in rats and found that DMT attenuated the electrophysiological signature neurodegeneration even when 5-HTR binding was inhibited with a serotonergic antagonist, which confirmed the neuroprotective role of Sig-1R activation in their hypothesis.

Published
May 21, 2021
Journal
Neuropharmacology
Authors
Szabó, Í., Varga, V. É., Dvorácskó, S., Farkas, A. E., Körmöczi, T., Berkecz, R., Kecskés, S., Menyhárt, Á., Frank, R., Hantosi, D., Cozzi, N. V., Frecska, E., Tömböly, C., Krizbai, I. A., Bari, F., Farkas, E.
Open Accessindividual

Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey

In a large international self‑selecting online survey (n = 96,901), past‑year ayahuasca users (n = 527) reported greater well‑being than both classic psychedelic users and non‑psychedelic drug users, and less problematic alcohol use than classic psychedelic users. Ayahuasca’s acute subjective effects typically lasted about six hours and were strongest around one hour after consumption.

Published
November 9, 2017
Journal
Scientific Reports
Authors
Lawn, W., Hallak, J. E., Crippa, J. A., Santos, R. D., Porffy, L., Barratt, M. J., Ferris, J. A., Winstock, A. R., Morgan, C. J. A.
Open Accessmeta

Dimethyltryptamine (DMT): a biochemical Swiss Army knife in neuroinflammation and neuroprotection?

This commentary reviews the role of DMT as an endogenous ligand of the Sigma-1 receptor, and although the exact physiological role of endogenous DMT is yet to be identified, there is evidence that suggests that it can modulate immune responses through the suppression of inflammatory cytokines. These neuroprotective and neuroregenerative effects may render DMT a potentially useful therapeutic tool in a broad range of chronic inflammatory and autoimmune diseases.

Published
January 1, 2016
Journal
Neural Regeneration Research
Authors
Szabo, A., Frecska, E.

Clinical Trials

0 trials

No clinical trials have been tagged with both DMT and Neurocognitive Disorders yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all DMT papers Search all Neurocognitive Disorders trials Full DMT profile Full Neurocognitive Disorders profile